835 related articles for article (PubMed ID: 29048477)
21. Enterotoxic Clostridia:
Mileto S; Das A; Lyras D
Microbiol Spectr; 2019 May; 7(3):. PubMed ID: 31124432
[No Abstract] [Full Text] [Related]
22. Study of the frequency of Clostridium difficile tcdA, tcdB, cdtA and cdtB genes in feces of Calves in south west of Iran.
Doosti A; Mokhtari-Farsani A
Ann Clin Microbiol Antimicrob; 2014 Jun; 13():21. PubMed ID: 24903619
[TBL] [Abstract][Full Text] [Related]
23. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
24. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
25. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
26. Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota.
Fletcher JR; Pike CM; Parsons RJ; Rivera AJ; Foley MH; McLaren MR; Montgomery SA; Theriot CM
Nat Commun; 2021 Jan; 12(1):462. PubMed ID: 33469019
[TBL] [Abstract][Full Text] [Related]
27. The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins.
Erickson SL; Alston L; Nieves K; Chang TKH; Mani S; Flannigan KL; Hirota SA
FASEB J; 2020 Feb; 34(2):2198-2212. PubMed ID: 31907988
[TBL] [Abstract][Full Text] [Related]
28. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
[TBL] [Abstract][Full Text] [Related]
29. Difference in F-actin depolymerization induced by toxin B from the Clostridium difficile strain VPI 10463 and toxin B from the variant Clostridium difficile serotype F strain 1470.
May M; Wang T; Müller M; Genth H
Toxins (Basel); 2013 Jan; 5(1):106-19. PubMed ID: 23344455
[TBL] [Abstract][Full Text] [Related]
30. An Update on
Martínez-Meléndez A; Cruz-López F; Morfin-Otero R; Maldonado-Garza HJ; Garza-González E
Toxins (Basel); 2022 Apr; 14(5):. PubMed ID: 35622552
[TBL] [Abstract][Full Text] [Related]
31. An Updated View on the Cellular Uptake and Mode-of-Action of Clostridioides difficile Toxins.
Papatheodorou P; Minton NP; Aktories K; Barth H
Adv Exp Med Biol; 2024; 1435():219-247. PubMed ID: 38175478
[TBL] [Abstract][Full Text] [Related]
32. The microbial metabolite urolithin A reduces
Ghosh S; Erickson D; Chua MJ; Collins J; Jala VR
mSystems; 2024 Feb; 9(2):e0125523. PubMed ID: 38193707
[No Abstract] [Full Text] [Related]
33. Host recognition of Clostridium difficile and the innate immune response.
Cowardin CA; Petri WA
Anaerobe; 2014 Dec; 30():205-9. PubMed ID: 25223264
[TBL] [Abstract][Full Text] [Related]
34. Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A.
Cowardin CA; Jackman BM; Noor Z; Burgess SL; Feig AL; Petri WA
Infect Immun; 2016 Aug; 84(8):2317-2323. PubMed ID: 27271747
[TBL] [Abstract][Full Text] [Related]
35. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
36. Clostridial toxins: sensing a target in a hostile gut environment.
Oezguen N; Power TD; Urvil P; Feng H; Pothoulakis C; Stamler JS; Braun W; Savidge TC
Gut Microbes; 2012; 3(1):35-41. PubMed ID: 22356854
[TBL] [Abstract][Full Text] [Related]
37. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
[TBL] [Abstract][Full Text] [Related]
38. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
[TBL] [Abstract][Full Text] [Related]
39. Mouse relapse model of Clostridium difficile infection.
Sun X; Wang H; Zhang Y; Chen K; Davis B; Feng H
Infect Immun; 2011 Jul; 79(7):2856-64. PubMed ID: 21576341
[TBL] [Abstract][Full Text] [Related]
40. Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.
Steele J; Mukherjee J; Parry N; Tzipori S
J Infect Dis; 2013 Jan; 207(2):323-30. PubMed ID: 23125448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
